X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

ALVR

Closed

Allovir inc

9.81
+0.15 (+1.55%)
Last Update: 18 Mar 2025 23:00:00
Yesterday: 9.66
Day's Range: 9.55 - 10.32
Send
When Written:
 
3.94
Allovir Inc is a clinical-stage biotechnology company based in Cambridge, Massachusetts. It was founded in 2019 and is focused on developing and commercializing allogeneic, off-the-shelf, virus-specific T cell therapies for the treatment of viral diseases and cancers. The company's lead product candidate, Viralym-M, is a multi-virus specific T cell therapy in development for the treatment of six life-threatening viral infections, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Allovir's technology platform is based on the use of T cells that have been genetically modified to express high levels of virus-specific T cell receptors, which enables them to recognize and kill infected cells. The company is backed by top-tier investors, including Fidelity Management & Research Company, SoftBank Vision Fund, and BlackRock.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.11
X